MAYNE PHARMA GROUP LIMITED — Share Issue/Capital Change 2008

Jun 12, 2008

==> picture [118 x 112] intentionally omitted <==

NOTICE OF SHARES TO BE RELEASED FROM ESCROW

Friday 13 June 2008, Melbourne Australia : HalcyGen Pharmaceuticals Limited (ASX: HGN) in accordance with Listing Rule 3.10A, advise that 1,400,000 ordinary fully paid shares will be released from escrow on 29[th] June 2008

-ENDS-

Enquiries: Dr Roger Aston Craig Bottomley 0402 762 204 03 8614 7777

Rudi Michelson Monsoon Communications 0411 402 737

Background on HalcyGen:

HalcyGen has been founded to bridge the gap between mainline pharmaceutical companies and high volume generics companies through the development and licensing of new improved proprietary generic formulations known as "Super Generics" or "High Functionality Generics". HalcyGen's strategy is to capitalise on the value associated with the development and commercialisation of novel, improved variants of existing proprietary pharmaceuticals known as Super Generics.

The basis of the HalcyGen's strategy is a strategic licensing partnership with Hospira, Inc. The Company will initially develop and market two products in partnership with Hospira. Subject to performance and meeting certain other criteria, the Company has the opportunity to develop further products with Hospira, Inc.

Through the global exclusive license granted to HalcyGen by Hospira, Inc., for the commercialisation of SUBA™Itraconazole, Hospira has a first right of refusal to manufacture SUBA™-Itraconazole to support sales. Hospira is a global specialty pharmaceutical and medication delivery company.